Opinion

Video

Use of Molecular Biomarkers Tests

The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.

Video content above is prompted by the following question:

  • What role do biomarkers play in quantifying the benefits and risks of therapy for prostate cancer patients? (Angelo A. Baccala, MD)
    • Briefly discuss the use of molecular biomarkers tests, such as Prolaris, in predicting the absolute benefit in risk of metastasis of ADT added to radiation therapy in newly diagnosed prostate cancer patients.
Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Related Content
© 2025 MJH Life Sciences

All rights reserved.